by According to Precedence Research, during the forecast period of 2022 to 2030, the global cardiovascular drugs market is estimated to develop at a compound annual growth rate (CAGR) of 4.52%. The global cardiovascular drugs market was valued at USD 155.6 billion in 2021, and it is predicted to exceed USD 231.7 billion by 2030. The study investigates several elements and their consequences on the growth of the cardiovascular drugs market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/2037
This report focuses on cardiovascular drugs market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall cardiovascular drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Report Scope of the Cardiovascular Drugs Market
| Report Coverage | Details |
| Market Size in 2022 | USD 162.64 Billion |
| Market Size by 2030 | USD 231.7 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.52% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Type, Disease Indication, Route of Administration, Drug, Mode of Purchase, End Users, Geography |
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of cardiovascular drugs, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of cardiovascular drugs has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the cardiovascular drugs market.
Some of the prominent players in the cardiovascular drugs market include:
- Bristol-Myers Squibb Company
- Bayer AG
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Novartis AG
- Merck & Co.
- AstraZeneca
- Sanofi
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/2037
Segments Covered in the Report
By Drug Type
- Antihypertensive
- Anticoagulants
- Antihyperlipidemic
- Antiplatelet Drugs
- Others
By Disease Indication
- Hypertension
- Coronary Artery Disease
- Hyperlipidaemia
- Arrhythmia
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Drug Classification
- Branded Drugs
- Generic Drugs
By Mode of Purchase
- Prescription-Based Drugs
- Over-The-Counter Drugs
By End Users
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. End Users Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cardiovascular Drugs Market
5.1. COVID-19 Landscape: Cardiovascular Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cardiovascular Drugs Market, By Drug Type
8.1. Cardiovascular Drugs Market, by Drug Type, 2022-2030
8.1.1. Antihypertensive
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Anticoagulants
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Antihyperlipidemic
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antiplatelet Drugs
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cardiovascular Drugs Market, By Disease Indication
9.1. Cardiovascular Drugs Market, by Disease Indication, 2022-2030
9.1.1. Hypertension
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Coronary Artery Disease
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hyperlipidaemia
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Arrhythmia
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cardiovascular Drugs Market, By Route of Administration
10.1. Cardiovascular Drugs Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cardiovascular Drugs Market, By Drug Classification
11.1. Cardiovascular Drugs Market, by Drug Classification, 2022-2030
11.1.1. Branded Drugs
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Generic Drugs
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cardiovascular Drugs Market, By Mode of Purchase
12.1. Cardiovascular Drugs Market, by Mode of Purchase, 2022-2030
12.1.1. Prescription-Based Drugs
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Over-The-Counter Drugs
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Cardiovascular Drugs Market, By End Users
13.1. Cardiovascular Drugs Market, by End Users, 2022-2030
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Online Pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Retail Pharmacies
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Others
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Cardiovascular Drugs Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.6. Market Revenue and Forecast, by End Users (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.11. Market Revenue and Forecast, by End Users (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.6. Market Revenue and Forecast, by End Users (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.10.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.12. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.13. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.14. Market Revenue and Forecast, by End Users (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.15.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.16. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.16.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.17.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.18. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.18.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.9. Market Revenue and Forecast, by End Users (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.11.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.12.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.9. Market Revenue and Forecast, by End Users (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.12. Market Revenue and Forecast, by End Users (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.14.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.9.6. Market Revenue and Forecast, by End Users (2017-2030)
Chapter 15. Company Profiles
15.1. Bristol-Myers Squibb Company
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Bayer AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Janssen Pharmaceuticals, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Novartis AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Merck & Co.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. AstraZeneca
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Gilead Sciences, Inc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. F. Hoffmann-La Roche
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/2037
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
